Karyopharm posts q2 preliminary product sales for xpovio of $18.5 mln

Karyopharm announces preliminary unaudited second quarter product sales for xpovio® (selinexor).karyopharm therapeutics - preliminary unaudited xpovio net product sales of about $18.5 million for q2 2020.karyopharm therapeutics - prescription refill rates, as well as average number of prescriptions per patient, continued to grow during quarter.
KPTI Ratings Summary
KPTI Quant Ranking